Cat. No.: HY-181076

FOXM1-IN-3

Name: FOXM1-IN-3
Brand: MedChemExpress
SKU: HY-181076
Price: 470.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Customer Review

Based on 1 Customer Validation

FOXM1-IN-3 is a potent FOXM1 inhibitor. FOXM1-IN-3 downregulates FOXM1 expression at protein and mRNA levels, suppressing downstream effectors CCNB1 and CDC25. FOXM1-IN-3 induces G2/M cell cycle arrest and apoptosis in colorectal cancer cells. FOXM1-IN-3 inhibits colony formation and cell migration in colorectal cancer cells. FOXM1-IN-3 targets the cancer stem cell phenotype in colorectal cancer cells, reducing cancer stem cell marker expression. FOXM1-IN-3 reduces tumor growth in a zebrafish xenograft model. FOXM1-IN-3 can be used for the research of colorectal cancer.

For research use only. We do not sell to patients.

Purity : 99.59%
Formula: C₂₉H₃₈ClN₉O
Molecular Weight:564.12

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

FOXM1-IN-3 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

FOXM1

PI3Kγ

3.5 μM (IC₅₀)

All PI3K Isoforms :

All CDK Isoforms :

In Vitro

FOXM1-IN-3 (compound 14) (6.25-100 μM; 24 h) potently inhibits proliferation in SW620 and SW480 colorectal cancer cells with IC₅₀ values of 14.9 μM and 17.5 μM, respectively, and shows favorable selectivity over normal CCD841 cells (IC₅₀ of 36.65 μM)^[1].
FOXM1-IN-3 (0.75-3 μM; 7 days) almost completely inhibits colony formation in SW480 and SW620 cells at 3 μM, reflecting long-term antiproliferative effects^[1].
FOXM1-IN-3 (6.25-25 μM; 48 h) suppresses cell migration in SW480 cells at 6.25 μM and in SW620 cells at 12.5 μM over 48 h^[1].
FOXM1-IN-3 shows measurable inhibition of PI3Kβ, γ, and δ^[1].
FOXM1-IN-3 (6.25-25 μM; 24 h) downregulates FOXM1 and its downstream effectors CCNB1 and CDC25 in SW480 and SW620 cells at concentrations as low as 6.25 μM^[1].
FOXM1-IN-3 (6.25-25 μM; 24 h) causes G₂/M phase arrest in SW480 and SW620 cells, correlating with FOXM1 downregulation^[1].
FOXM1-IN-3 (6.25-25 μM; 24 h) induces apoptosis in SW480 and SW620 cells at 12.5 μM and 25 μM^[1].
FOXM1-IN-3 (10 μM; 24 h, 48 h) selectively targets cancer stem cell (CSC) phenotypes in SW480 and SW620 cells at 10 μM, with mild and reversible effects on normal CCD841 cells^[1].
FOXM1-IN-3 has high passive permeability, low CYP interference, notable hepatotoxicity (IC₅₀ ~5.6 μM in HepG2), and lower neurotoxicity (IC₅₀ ~17 μM in SH-SY5Y)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

SW620, SW480, CCD841
Concentration:

100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM
Incubation Time:

24 h
Result:

Demonstrated antiproliferative effects with IC₅₀ values of 14.9 μM (SW620), 17.5 μM (SW480), and 36.7 μM (CCD841), yielding selectivity indices of 2.1-2.5.

Cell Migration Assay^[1]

Cell Line:

SW480, SW620
Concentration:

25 μM, 12.5 μM, 6.25 μM
Incubation Time:

48 h
Result:

Significantly impaired migration ability, with inhibition observed at 6.25 μM in SW480 cells and at 12.5 μM in SW620 cells.

Cell Cycle Analysis^[1]

Cell Line:

SW480, SW620
Concentration:

25 μM, 12.5 μM, 6.25 μM
Incubation Time:

24 h
Result:

Induced a dose-dependent accumulation of cells in the G₂/M phase along with a significant reduction in the S phase population in both cell lines.

Apoptosis Analysis^[1]

Cell Line:

SW480, SW620
Concentration:

25 μM, 12.5 μM, 6.25 μM
Incubation Time:

24 h
Result:

Increased levels of both early and late apoptotic cells in a dose-dependent manner, particularly at 12.5 μM and 25 μM.

In Vivo

FOXM1-IN-3 (compound 14) (5-10 μM; immersion; 72 hours) inhibits tumor growth in a zebrafish xenograft model, with the most pronounced effect in the SW620 line (80.95% tumor growth at 10 μM relative to control)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Zebrafish species Danio rerio (wild-type AB)^[1]
Dosage:

5, 10 μM
Administration:

immersion; 72 hours
Result:

For SW620 xenografts, showed 85.06% tumor growth relative to control at 5 μM and 80.95% at 10 μM at 3 days post-injection (dpi).
For SW480 xenografts, showed 92.65% tumor growth relative to control at 5 μM and 90.05% at 10 μM at 3 dpi.

Related Protocols :

Chemical Information

Appearance Solid
Molecular Weight 564.12
Formula C₂₉H₃₈ClN₉O
Color White to off-white
SMILES

C1(NCCC2=CNC3=C2C=CC=C3)=NC(NCCN4CCN(C5=CC=CC=C5)CC4)=NC(N6CCOCC6)=N1.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (59.08 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7727 mL

8.8634 mL

17.7267 mL

5 mM

0.3545 mL

1.7727 mL

3.5453 mL

10 mM

0.1773 mL

0.8863 mL

1.7727 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kułaga D, et al. Chemical modification of STL427944 toward morpholine-based 1,3,5-triazines as anticancer agents targeting FOXM1: green synthesis, biological evaluation and ADME-Tox profiling in a colorectal cancer model. Eur J Med Chem. 2026;304:118532. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7727 mL	8.8634 mL	17.7267 mL	44.3168 mL
	5 mM	0.3545 mL	1.7727 mL	3.5453 mL	8.8634 mL
	10 mM	0.1773 mL	0.8863 mL	1.7727 mL	4.4317 mL
	15 mM	0.1182 mL	0.5909 mL	1.1818 mL	2.9545 mL
	20 mM	0.0886 mL	0.4432 mL	0.8863 mL	2.2158 mL
	25 mM	0.0709 mL	0.3545 mL	0.7091 mL	1.7727 mL
	30 mM	0.0591 mL	0.2954 mL	0.5909 mL	1.4772 mL
	40 mM	0.0443 mL	0.2216 mL	0.4432 mL	1.1079 mL
	50 mM	0.0355 mL	0.1773 mL	0.3545 mL	0.8863 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

FOXM1-IN-3

All PI3K Isoforms

All CDK Isoforms